A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804

Cancer Chemotherapy and Pharmacology

Volumn 63, Issue 5, 2009, Pages 859-864

  Stone, Richard M ^a   Donohue, Kathleen A ^b   Stock, Wendy ^c   Hars, Vera ^b   Linker, Charles A ^d   Shea, Thomas ^e   DeAngelo, Daniel J ^a   Marcucci, Guido ^f   Bloomfield, Clara D ^f   Larson, Richard A ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f OHIO STATE UNIVERSITY   (United States)

Author keywords

Chronic myeloid leukemia; Cytarabine; Homoharringtonine

Indexed keywords

CYTARABINE; HOMOHARRINGTONINE; IMATINIB;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; INFECTION; LEUKEMIA REMISSION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTE TRANSFUSION; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; FEMALE; HARRINGTONINES; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 61449217041     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0805-8     Document Type: Article

References (21)

1. C Clopper E Pearson 1934 The use of confidence or fiducial limits illustrated in the case of binomial Biometrika 26 404 413
2. J Cortes 2004 Natural history and staging of chronic myelogenous leukemia Hematol Oncol Clin North Am 18 569 584
3. BJ Druker F Guilhot SG O'Brien I Gathmann H Kantarjian N Gattermann MW Deininger RT Silver JM Goldman RM Stone F Cervantes A Hochhaus BL Powell JL Gabrilove P Rousselot J Reiffers JJ Cornelissen T Hughes H Agis T Fischer G Verhoef J Shepherd G Saglio A Gratwohl JL Nielsen JP Radich B Simonsson K Taylor M Baccarani C So L Letvak RA Larson I Investigators 2006 Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia (see comment) N Engl J Med 355 2408 2417
4. JM Goldman JV Melo 2003 Chronic myeloid leukemia-advances in biology and new approaches to treatment N Engl J Med 349 1451 1464
5. ME Gorre M Mohammed K Ellwood N Hsu R Paquette PN Rao CL Sawyers 2001 Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification Science 293 876 880
6. F Guilhot C Chastang M Michallet A Guerci JL Harousseau F Maloisel R Bouabdallah D Guyotat N Cheron F Nicolini JF Abgrall J Tanzer M Navarro D Bordessoule P Morice N Ifrah H Rochant JP Vilque M Delain J Guilhot 1997 Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia N Engl J Med 337 223 229
7. ML Hensley B Peterson RT Silver RA Larson CA Schiffer TP Szatrowski 2000 Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013 J Clin Oncol 18 1301 1308
8. A Hochhaus HM Kantarjian M Baccarani JH Lipton JF Apperley BJ Druker T Facon SL Goldberg F Cervantes D Niederwieser RT Silver RM Stone TP Hughes MC Muller R Ezzeddine AM Countouriotis NP Shah 2007 Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy Blood 109 2303 2309
9. HM Kantarjian F Giles N Gattermann K Bhalla G Alimena F Palandri GJ Ossenkoppele FE Nicolini SG O'Brien M Litzow R Bhatia F Cervantes A Haque Y Shou DJ Resta A Weitzman A Hochhaus P le Coutre 2007 Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance Blood 110 3540 3546
10. HM Kantarjian M Talpaz TL Smith J Cortes FJ Giles MB Rios S Mallard J Gajewski A Murgo B Cheson S O'Brien 2000 Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia J Clin Oncol 18 3513 3521
11. EL Kaplan P Meier 1958 Nonparametric estimation from imcomplete observations J Am Stat Assoc 53 457 481
12. HJ Khoury M Michallet S Corm L Roy D Jones A Hochhaus H Kantarjian AC Benichou R Schwartz J Cortes 2007 Safety and efficacy study of subcutaneous homoharringtonine (SC HHT) in imatinib (IM)-resistant chronic myeloid leukemia with the T315I mutation-initial report of a phase II trial Blood 110 318a (abstract 1050)
13. Leukemia ICSGoCM 1994 Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia N Engl J Med 330 820 825
14. S O'Brien H Kantarjian M Keating M Beran C Koller LE Robertson J Hester MB Rios M Andreeff M Talpaz 1995 Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase Blood 86 3322 3326
15. S O'Brien M Talpaz J Cortes J Shan FJ Giles S Faderl D Thomas G Garcia-Manero S Mallard M Beth C Koller S Kornblau M Andreeff A Murgo M Keating HM Kantarjian 2002 Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia Cancer 94 2024 2032
16. PJ O'Dwyer SA King DF Hoth M Suffness B Leyland-Jones 1986 Homoharringtonine-perspectives on an active new natural product J Clin Oncol 4 1563 1568
17. MJ Robertson R Tantravahi JD Griffin GP Canellos SA Cannistra 1993 Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine Am J Hematol 43 95 102
18. M Schemper TL Smith 1996 A note on quantifying follow-up in studies of failure time Control Clin Trials 17 343 346
19. CA Schiffer 2007 BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia (see comment) N Engl J Med 357 258 265
20. W Stock D Yu T Karrison D Sher RM Stone RA Larson CD Bloomfield 2006 Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples Int J Oncol 28 1099 1103
21. M Talpaz HM Kantarjian K McCredie JM Trujillo MJ Keating JU Gutterman 1986 Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemia N Engl J Med 314 1065 1069